The Pentagon has issued a directive to screen roughly two million active‑duty and reserve service members who are 30 years of age or older for testosterone deficiency. The initiative, announced in a July memo from Secretary of War Pete Hegseth, is presented as a readiness measure designed to keep the force healthy, capable, and decisively dominant.
Guidance focuses on diagnosis, not performance enhancement
The Defense Health Agency’s clinical guidance, released this week, makes clear that testosterone is not being used as a performance enhancer. Instead, the guidance treats low testosterone as a medical condition that must be diagnosed through a symptom‑and‑risk‑factor questionnaire before any blood test is ordered. This approach aligns with established society guidelines and good clinical practice, according to Dr. Richard Auchus, an endocrinologist at the University of Michigan.
Dr. Auchus praised the guidance for avoiding blanket blood‑test screening of every individual over 30, noting that the document is “largely evidence‑based” and consistent with professional standards. He expressed relief that the policy does not recommend universal testing, but rather targets those who show symptoms or risk factors.
No cost estimate disclosed
While the program’s intent is clear, the Pentagon has not provided a cost estimate. Requests for a budget figure made in July and again this week were referred to the Pentagon press office, which has not responded. The guidance does not specify whether the screening and any subsequent treatment will be funded through the existing Military Health System budget or require a new appropriations request.
The House Armed Services Committee’s majority and minority offices have not yet commented on whether they have received a cost estimate for the program.
Origins in Operator Syndrome
The screening program traces its clinical premise to “Operator Syndrome,” a term coined in 2020 by psychologist Chris Frueh to describe a cluster of health issues—including brain injury, sleep disruption, and hormonal dysfunction—observed in special‑operations forces. Hegseth’s memo cited this syndrome as justification for extending testing across the broader force, and Frueh, who reviewed the new guidance, described it as “very good.”
Therapy benefits and limits
The guidance acknowledges that testosterone therapy can improve sexual function, body composition, and bone density for those diagnosed with deficiency. However, it also states that current evidence does not support its use for enhancing energy, vitality, physical function, or cognition. The American College of Physicians similarly recommends against prescribing testosterone for those performance‑related reasons, and a major clinical trial found no advantage over placebo in improving men’s energy or walking distance.
Secretary Hegseth’s July 15 memo emphasized that applying lessons learned from treating Operator Syndrome across the Total Force, including targeted testosterone therapy, directly optimizes warfighter readiness. Pentagon spokesman Sean Parnell echoed this sentiment on September 17, saying the effort will help sustain a “healthy, capable, and decisively dominant fighting force.”
What this means for service members
Service members age 30 and older can expect to be asked about symptoms and risk factors related to testosterone deficiency during routine medical visits. Only those who screen positive will be referred for blood testing and, if a deficiency is confirmed, for appropriate treatment. This targeted approach aims to safeguard the health of the force without unnecessary medical interventions.
As the program moves forward, service members and their families can look to the guidance’s evidence‑based framework as a sign that the Department of Defense is taking a measured, medically sound approach to maintaining the health and readiness of America’s warfighters.
Original reporting: KTBS 3 (Shreveport) — read the source article.
